World's Best Scientists 2026 revealed!
Fernando C. Fervenza

Fernando C. Fervenza

D-Index & Metrics

Medicine

D-Index
103
Citations
44293
World Ranking
7293
National Ranking
3819

Fernando C. Fervenza publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Fernando C. Fervenza sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 489 publications — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Fernando C. Fervenza D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Fernando C. Fervenza sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Fernando C. Fervenza is a researcher affiliated with the Mayo Clinic in the United States, specializing in the field of medicine, with a primary focus on nephrology. Their scholarly contributions are mainly concentrated in renal diseases and glomerulopathies, vasculitis and related conditions, as well as chronic kidney disease and diabetes. Other significant topics addressed in their work include coagulation, bradykinin, polyphosphates, and angioedema, amyloidosis diagnosis and treatment, complement system in diseases, and autoimmune bullous skin diseases.

Fervenza has authored numerous publications, notably appearing in prominent nephrology and renal medicine journals. Frequent publication venues include:

  • Journal of the American Society of Nephrology
  • Kidney International Reports
  • Kidney International
  • Nephrology Dialysis Transplantation
  • Clinical Journal of the American Society of Nephrology

Their recent notable papers include:

  • KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases, 2021, Kidney International
  • Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases, 2021, Kidney International
  • Membranous nephropathy, 2021, Nature Reviews Disease Primers
  • The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis, 2020, Nature Communications
  • Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients, 2020, Kidney International

Fernando C. Fervenza collaborates frequently with several researchers, reflecting a diverse network of academic partnerships. Their frequent co-authors include:

  • Sanjeev Sethi
  • Ladan Zand
  • Ulrich Specks
  • Samih H. Nasr
  • Marta Casal Moura

Their research spans multiple subfields such as pulmonary and respiratory medicine, genetics, molecular biology, and pathology and forensic medicine, contributing broadly to interdisciplinary medical sciences. This multidisciplinary approach complements their primary focus on nephrology and related renal pathologies.

Best Publications

  • Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

    John H. Stone;Peter A. Merkel;Robert Spiera;Philip Seo

  • Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study†

    Brad H. Rovin;Richard Furie;Kevin Latinis;R. John Looney

  • KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

    Brad H. Rovin;Sharon G. Adler;Jonathan Barratt;Frank Bridoux

  • The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification

    Daniel C. Cattran;Rosanna Coppo;H. Terence Cook;John Feehally

  • The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility

    Ian S.D. Roberts;H. Terence Cook;Stéphan Troyanov;Charles E. Alpers

  • Kidney disease: Improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis

    Daniel C. Cattran;John Feehally;H. Terence Cook;Zhi Hong Liu

  • Efficacy of Remission-Induction Regimens for ANCA-associated Vasculitis

    Ulrich Specks;Peter A. Merkel;Philip Seo;Robert Spiera

  • Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

    Timothy H.J. Goodship;H. Terence Cook;Fadi Fakhouri;Fernando C. Fervenza

  • C3 glomerulopathy: consensus report

    Matthew C. Pickering;Vivette D. D'agati;Carla M. Nester;Richard J. Smith

  • Membranoproliferative Glomerulonephritis — A New Look at an Old Entity

    Sanjeev Sethi;Fernando C. Fervenza

  • Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.

    Laurence H. Beck;Fernando Custodio Fervenza;David M. Beck;Ramon G B Bonegio

  • Rituximab for Refractory Wegener's Granulomatosis: Report of a Prospective, Open-Label Pilot Trial

    Karina A. Keogh;Steven R. Ytterberg;Fernando C. Fervenza;Kimberly A. Carlson

  • Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.

    Brad H. Rovin;Sharon G. Adler;Jonathan Barratt;Frank Bridoux

  • The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

    Nelson Leung;Frank Bridoux;Vecihi Batuman;Aristeidis Chaidos

  • Diagnosis of monoclonal gammopathy of renal significance

    Frank Bridoux;Nelson Leung;Colin A. Hutchison;Guy Touchard

  • Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy

    Fernando C. Fervenza;Gerald B. Appel;Sean J. Barbour;Brad H. Rovin

  • Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

    Ulrich Specks;Fernando C. Fervenza;Thomas J. McDonald;Marie C. E. Hogan

  • C3 glomerulonephritis: Clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up

    Sanjeev Sethi;Fernando C. Fervenza;Yuzhou Zhang;Ladan Zand

  • The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society:

    Daniel C. Cattran;Rosanna Coppo;H. Terence Cook;John Feehally

  • ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) CONTROVERSIES CONFERENCE

    Timothy H.J. Goodship;H. Terence Cook;Fadi Fakhouri;Fernando C. Fervenza

Frequent Co-Authors

Sanjeev Sethi
Sanjeev Sethi Mayo Clinic
Nelson Leung
Nelson Leung Mayo Clinic
Ulrich Specks
Ulrich Specks Mayo Clinic
Samih H. Nasr
Samih H. Nasr Mayo Clinic
John H. Stone
John H. Stone Harvard University
Richard J.H. Smith
Richard J.H. Smith University of Iowa
Daniel C. Cattran
Daniel C. Cattran University Health Network
E. William St. Clair
E. William St. Clair Duke University
Gary S. Hoffman
Gary S. Hoffman Cleveland Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up a wide range of related online degree options and alternative pathways. For those interested in nursing but concerned about exam requirements, there are nursing schools that don't require teas test, making entry more accessible for some prospective students.

If leadership and management in healthcare appeal to you, consider enrolling in an accelerated healthcare administration degree online. These programs are designed for those who wish to quickly advance into administrative or managerial roles within healthcare systems.

For licensed nurses aiming to become nurse practitioners, ASN holders can explore tailored bridge programs, such as an asn to np degree pathway. This route helps streamline the process of earning an MSN and expanding clinical capabilities.

Nutrition and food science are also promising fields, especially with flexible learning options. Discover the best online food science degree programs to find opportunities in research, public health, or the food industry.

Best Scientists Citing Fernando C. Fervenza

Trending Scientists

Recently Published Articles